Inactive Instrument

Bioverativ Inc Stock

Equities

US09075E1001

Biotechnology & Medical Research

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Chart Bioverativ Inc

Duration

Period

Style

Latest news about Bioverativ Inc

Sanofi : sees new acquisitions and drugs reviving growth	18-04-27	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	18-03-29	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	18-03-29	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	18-03-28	RE
Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	18-02-15	RE
Ablynx : Sanofi's return to profit growth this year slower than hoped	18-02-07	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	18-01-29	RE
Stocks hit record as senators reach deal to end shutdown	18-01-22	RE
Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	18-01-22	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	18-01-22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	18-01-22	RE
Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	18-01-22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	18-01-22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	18-01-22	RE
Bioverativ : Sanofi shares fall on $11.6 billion Bioverativ takeover	18-01-22	RE

Press releases Bioverativ Inc

Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	18-03-06	BU
Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	18-02-14	BU
Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	18-02-13	BU
WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	18-01-24	PR
Bragar Eagel & Squire, P.C. : is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm	18-01-22	BU

More press releases

News in other languages on Bioverativ Inc

Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril	18-03-29
Sanofi finalise l'acquisition de Bioverativ	18-03-08
Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse	18-03-08
Sanofi : franchit une étape dans son offre sur Bioverativ	18-02-23
Sanofi: Amélioration attendue en 2018 plus lente que prévu	18-02-07

Managers and Directors - Bioverativ Inc

Managers	Title	Age	Since
William Sibold PSD	President	-	18-03-07
Joann Nestor SEC	Corporate Secretary	-	-
Timothy J.R. Harris PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
William Sibold PSD	President	-	18-03-07
Philippe Sauvage BRD	Director/Board Member	-	18-03-07

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+10.44%	106B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	104B
ARGENX SE	+6.72%	23.25B
BIONTECH SE	-13.89%	22.5B
GENMAB A/S	-6.64%	18.7B
WUXI APPTEC CO., LTD.	-37.26%	17.95B
BEIGENE, LTD.	-10.98%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.76B

Bio Therapeutic Drugs

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW